[Source: Trading Markets] – ImmuneRegen BioSciences Inc. has signed an agreement with the National Institute of Health (NIH) / National Cancer Institute (NCI), to commence studies utilizing its Homspera. All the partners are based in the US.
ImmuneRegen is a wholly-owned subsidiary of IR Biosciences Holdings, Inc., a biotechnology company.
Under the agreement, the NIH will perform exploratory studies on Homspera relating to mucosal immunity that might lead to subsequent evaluation in models of human immunodeficiency virus infection. The studies to be performed at NIH/NCI are designed to define the mechanisms that make Homspera an effective vaccine adjuvant.
For more information: ImmuneRegen BioSciences signs research agreement with National Cancer Institute